Heart Failure Management Strategies and Therapeutics

Heart failure represents a global health challenge, characterised by the heart’s inability to supply sufficient blood flow to meet metabolic demands. Contemporary management spans pharmacological, device-based and system-level strategies. Foundational drug classes include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and beta-adrenergic blockers, which interrupt maladaptive neurohormonal activation. Mineralocorticoid receptor antagonists and more recently combined angiotensin receptor–neprilysin inhibitors further reduce morbidity and mortality. Sodium–glucose cotransporter 2 inhibitors now provide cardiorenal protection across ejection-fraction subgroups. Device therapies such as cardiac resynchronisation, implantable defibrillators and mechanical circulatory support address electrical dyssynchrony and pump failure in advanced stages. Non-pharmacological measures—exercise rehabilitation, dietary sodium restriction and remote monitoring—optimise self-care and early detection of decompensation. Multidisciplinary service models integrate cardiologists, primary care physicians, specialised nurses and allied health professionals to deliver guideline-directed care while tackling comorbidity. Looking forward, precision medicine approaches including gene therapy, novel biomarkers and regenerative strategies promise to refine risk stratification and tailor interventions. The synergy of established agents, innovative therapeutics and care delivery redesign underpins substantial progress in heart failure outcomes.

Research from Nature Portfolio

Recent studies have elucidated cellular and molecular targets for cardiac regeneration, demonstrating that modulation of macrophage-driven inflammation can improve post-infarct remodelling and prevent progression to chronic heart failure. Cutting-edge work on engineered tissue patches infused with cardiac progenitor cells has shown enhanced contractile function in preclinical models. Advances in machine-learning algorithms applied to electrocardiographic and imaging data have enabled early identification of patients at imminent risk of decompensation, facilitating proactive adjustment of therapy and reducing hospitalisation rates. Novel small-molecule inhibitors of pathological myocardial fibrosis have entered phase III trials, offering the prospect of myocardial structural reversal and improved ejection performance.

Heart Failure Management Strategies and Therapeutics publication trend

The graph below shows the total number of articles in heart failure management strategies and therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Ejection fraction: Proportion of blood ejected from the left ventricle during systole, used to categorise heart failure.

Angiotensin receptor–neprilysin inhibitor (ARNI): Combination therapy that blocks angiotensin II receptors while inhibiting neprilysin to enhance natriuretic peptide levels.

Sodium–glucose cotransporter 2 (SGLT2) inhibitor: Drug class originally for diabetes that reduces heart failure hospitalisations via cardiorenal protective mechanisms.

Cardiac resynchronisation therapy (CRT): Biventricular pacing device that improves synchrony of ventricular contraction in selected heart failure patients.

Left ventricular assist device (LVAD): Mechanical pump that supports or replaces left ventricular function in advanced heart failure.

Heart failure with preserved ejection fraction (HFpEF): Syndrome in which diastolic dysfunction and stiffness impair ventricular filling despite normal ejection fraction.

NO-cGMP-PKG axis: Molecular signalling pathway regulating vasodilation and myocardial relaxation, therapeutic target in HFpEF.

Multidisciplinary rounds: Structured team meetings involving diverse health professionals to coordinate inpatient care and decision-making.

References

1. Challenges in personalised management of chronic diseases—heart failure as prominent example to advance the care process. EPMA Journal (2015).
2. The NO-cGMP-PKG Axis in HFpEF: From Pathological Mechanisms to Potential Therapies. Aging and Disease (2023).
3. Specialized multi-disciplinary heart failure clinics in Ontario, Canada: an environmental scan. BMC Health Services Research (2012).
4. Heart failure management insights from primary care physicians and allied health care providers in Southwestern Ontario. BMC Primary Care (2020).
5. The association between implementation of multidisciplinary rounds and clinical outcomes. Frontiers in Cardiovascular Medicine (2022).